Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II study of GT201 autologous tumor-infiltrating lymphocyte injection alone or with a PD-1 inhibitor in advanced solid tumors
CTR20233098Phase 2Active
- Sponsor
- Grit Biotherapeutics
- Start
- Nov 2025
- Modality
- Tumor-Infiltrating Lymphocytes (TILs) → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies
- Countries
- 1
01
Overview
Phase 2, open-label trial of GT201 in Nonhematologic neoplasms (2 arms), sponsored by Grit Biotherapeutics. Primary endpoints: Safety of GT201 alone and in combination and Efficacy of GT201 alone or with a PD-1 inhibitor in target indications. Started Nov 2025; status: active.
02
Drugs
GT201
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on CTR20233098.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20233098.